Is NewAmsterdam Pharma Company N.V. (NAMS) Overvalued?
We dive into why NewAmsterdam Pharma Company N.V. (NAMS) could be considered overvalued on 2026-07-31, based on AAII’s Value Score and Grade.Tudor Pop
Stock Evaluator: NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V. NAMS
$25.84
0.25
0.98%
September 3, 2026 10:46:13 AM
EST
Volume: 77,949
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Commentary & Analysis
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Down 5.51%
As of Tuesday, July 28, NewAmsterdam Pharma Company N.V.’s NAMS share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 5.69%
As of Wednesday, May 20, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 5.69%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 7.28%
As of Monday, May 11, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 7.28%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 6.66%
As of Friday, May 08, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 6.66%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,059.0 | $288.9 | 60% |
|
| Shares Out (Mil) | 123.4 | 54.0 | 66% |
|
| Institutional Ownership | 99.6% | 93.1% | 91% |
|
| Float (Mil) | 82.6 | 41.4 | 57% |
|
| Beta | 0.11 | 0.94 | 9% |
|
| Avg Daily Volume (000s) | 1,007 | 480 | 72% |
|
| Price Change (52-week) |
3.9% | 59.9% | 50% |
|
| Growth | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (96.3%) | (10.1%) | 2% |
|
| EPS (5yr) | (4.1%) | 15.9% | 26 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.3%) | (15.6%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 12 | 11 | |
| Current EPS | na | ($1.919) | ($1.562) | |
| Month Ago EPS | na | ($1.856) | ($1.306) | |
| # Rev Up | na | 2 | 2 | |
| # Rev Down | na | 1 | 1 | |
| Three Months Ago EPS | na | ($1.836) | ($1.287) | |
| Year/Year Chg | na | 11.5% | na | |
| Financials | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($260) | ($43) | 5% |
|
| EPS (TTM) | ($2.144) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($144) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($138) | $2 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $2,547 | $190 | 52% |
|
| Valuation | NAMS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.77 | 2.84 | 77% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (34.2%) | (47.7%) | 16% |
|
| ROE | (36.8%) | (55.0%) | 18% |
|
| Liabilities to Assets | 10.4% | 29.6% | 6% |
|
| F-Score | 3 | 3 | 18% |
|
NewAmsterdam Pharma Company N.V. did not pass any screens on 9/2/2026.
